Pomalidomide is a third-generation immunomodulatory drug (IMiD) of the thalidomide analogue class, exerting direct antimyeloma and immune-modulating effects through cereblon-mediated protein degradation pathways, used for relapsed/refractory multiple myeloma. Simson Pharma's Pomalidomide reference standard and impurities support the stringent QC and risk-management testing this oncology agent requires.
Simson Pharma Global Ltd. (UK) and Simson Pharma Global LLC (USA) supply high-quality Pomalidomide Reference Standards, pharmacopoeial reference materials, and its related impurities to pharmaceutical manufacturers, CROs, analytical laboratories, universities, and regulatory organizations worldwide. To service the Europe and America market efficiently, Simson Pharma Limited has set up Simson Pharma Global Ltd. in United Kingdom and Simson Pharma Global LLC in USA respectively.